CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

By /

CNS Pharmaceuticals, Inc. today announced completion of planned enrollment in its global potentially pivotal study evaluating Berubicin.

Scroll to Top